Targovax to present at the World Immunotherapy Congress

Oslo, 2 November 2020 – Targovax ASA, today announces that Magnus Jäderberg, CMO of Targovax, will present the company at the World Immunotherapy Congress today, Monday 2 November, at 11:20 CET.

The presentation will be available to download at www.targovax.com after the event.

About the event

The World Immunotherapy Congress is part of the Festival of Biologics. The Festival of Biologics is the meeting place for the life science community to bridge the gap between academia and industry.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
 

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.